Patrick Loerch

One of the biggest blind spots for early-stage biotechs is what happens on the other side of the table. Building extraordinary science is not the same as navigating clinical development, managing the tradeoffs of an R&D portfolio or preparing to bring a therapy to patients. 

Patrick brings a perspective that is rare in the venture world. He began his career at Rosetta Inpharmatics, a genomics pioneer behind  expression profiling before its acquisition by Merck. Over the next two decades, he built and led data science organizations across some of the industry’s most respected pharma companies like Merck, Celgene, and J&J/Janssen. Along the way, he also co-founded Shift Medical, a clinical health tech software provider. 

Today, Patrick serves as SVP of Clinical Data Science at Gilead Sciences, where as he oversees Biometrics, Clinical Bioinformatics, Real World Evidence, Clinical Pharmacology and is deeply involved in the broader buildout of the company’s AI capabilities. He is also a member of Gilead’s Research and Development portfolio committees.

Patrick’s PhD in Biostatistics from Harvard, along with his early research on aging brain transcriptomics give him deep scientific fluency. But what makes him especially valuable to Amplify founders is his operating perspective on how ambitious biology translates to novel therapies.